Gritstone bio wins $433 million US award for COVID vaccine study

Gritstone bio

27/09/2023 21:05

Sept 27 (Reuters) - Gritstone bio  GRTS.O  on Wednesday
secured a $433 million contract by the U.S. government to
conduct a mid-stage study of its self-amplifying mRNA COVID-19
vaccine candidate.
    The agreement comes as a part of the "Project NextGen," an
initiative by the U.S. Department of Health and Human Services
(HHS) to advance a pipeline of new, innovative vaccines and
therapeutics providing broader and more durable protection 
against COVID-19 infection.
    The contract is awarded by the Biomedical Advanced Research
and Development Authority (BARDA), a U.S. federal agency that
funds disease-fighting technology. 




 (Reporting by Sriparna Roy in Bengaluru; Editing by Shweta
Agarwal)
 ((Sriparna.Roy@thomsonreuters.com;))